Immunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 Study

Immunovant shares hit a new 52-week high Monday after the clinical-stage immunology company said it received U.S. Food and Drug Administration approval to conduct a Phase 1 study of its IMVT-1402 drug candidate for autoimmune disease.